Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente Langdahl(Aarhus University Hospital), Cesar Libanati(UCB Pharma (Belgium)), Daria B. Crittenden(Amgen (United States)), Michael A. Bolognese, Jacques P. Brown(Université Laval), Nadia Daizadeh(Amgen (United States)), Eva Dokoupilová(Medical Plus), Klaus Engelke, Joel S. Finkelstein(Massachusetts General Hospital), Harry K. Genant(University of California, San Francisco), Stefan Goemaere(Ghent University Hospital), Lars Hyldstrup(Hvidovre Hospital), Esteban Jódar-Gimeno(Universidad Europea), Tony M. Keaveny(University of California, Berkeley), David L. Kendler(University of British Columbia), Péter Lakatos(Semmelweis University), Judy Maddox(Amgen (United States)), Jorge Malouf(Universitat Autònoma de Barcelona), Fabio Massari(Instituto de Diagnóstico e Investigaciones Metabólicas), José Fernando Molina(Fundacion Instituto de Reumatologia Fernando Chalem), María Rosa Ulla, Andreas Grauer(Amgen (United States))
Cited by 463
Abstract
Related Papers
No related papers found
Powered by citation graph analysis